ClinicalTrials.gg
CompletedNCT05849922HS OBTAINUpdated Jan 29, 2026Results posted

A Study to Test the Efficacy and Safety of SAR442970 in Adults With Hidradenitis Suppurativa

A Phase 2 interventional study of SAR442970 and Placebo in Hidradenitis Suppurativa, sponsored by Sanofi. Completed at 45 sites in 15 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-01-29.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
86
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 161 studies in Hidradenitis Suppurativa with a site in United States — 38 open to participants now, 55 under way, 12 of them phase 3. Hidradenitis Suppurativa · United States.

Enrollment
57th of 139
86 · median 45
Started
2023
with 12 others
Phase 2
61 of 161
11 open now
Registered
101st of 161
by date

Among the 161 studies in Hidradenitis Suppurativa with a site in United States, this one is the 57th largest by enrollment of the 139 interventional ones that give a count, is one of 13 that started in 2023, is one of 61 in phase 2, and was the 101st registered.

Hidradenitis Suppurativa

285 studies on the registry are indexed under Hidradenitis Suppurativa; 88 are open to participants now.

Browse Hidradenitis Suppurativa studies →

Open to participants now

38 of the 161 studies in Hidradenitis Suppurativa with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 61 Hidradenitis Suppurativa studies recruiting now, 33 (54%) set no upper age limit and 17 (28%) stop at 75 or younger; 13 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 161 studies in Hidradenitis Suppurativa with a site in United States, or all of them as a file.
02

Study summary

This was a Phase 2 study in adult participants with moderate to severe hidradenitis suppurativa (HS). The purpose of the study was to evaluate the efficacy and safety of SAR442970 compared to placebo.

Read the detailed description

The study duration was up to 40 weeks.

03

Conditions studied

  • Hidradenitis Suppurativa
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with a history of signs and symptoms consistent with hidradenitis suppurativa (HS) for at least 1 year prior to Baseline.
  • Participants had to have HS lesions present in at least 2 distinct anatomic areas (eg, left and right axilla; or left axilla and left inguinocrural fold), one of which had to be Hurley Stage II or Hurley Stage III.
  • Participant had to have had an inadequate response to a trial of an oral antibiotic for treatment of HS, exhibited recurrence after discontinuation of antibiotics, demonstrated intolerance to antibiotics, or had a to oral antibiotics for treatment of their HS as assessed by the Investigator through participant interview and review of medical history.
  • Participants had to be either biologic and small molecule -naïve or TNF-experienced.
  • Participant had to have a total abscess and inflammatory nodule (AN) count of ≥3 at the Baseline visit.
  • Participant had to have a draining tunnel count of ≤20 at the Baseline visit.
  • Participant had to have a C-reactive protein (CRP) >3 mg/L at the screening visit.
  • Participant who was a candidate for systemic treatment per Investigator's judgment.

Exclusion criteria

Exclusion Criteria:

  • Any other active skin disease or condition (eg, bacterial, fungal or viral infection) that might have interfered with assessment of HS
  • History of recurrent or recent serious infection
  • Known history of or suspected significant current
  • History of solid organ transplant
  • History of splenectomy
  • History of moderate to severe congestive heart failure
  • Receipt of a 12 week prior to Baseline visit or receipt of a killed vaccine 2 weeks prior to Baseline visit
  • History of demyelinating disease (including myelitis) or neurologic symptoms suggestive of demyelinating disease
  • Participants with a history of or lymphoproliferative disease other than adequately treated or nonmetastatic squamous cell carcinoma, or nonmetastatic basal cell carcinoma of the skin that was excised and completely cured
  • Participants with a diagnosis of inflammatory conditions other than HS
  • Presence of active suicidal ideation, or positive suicide behavior or participant had a lifetime history of suicide attempt, or participant had had suicidal ideation in the past 6 months as indicated by a positive response using the screening or Baseline version of the Columbia-Suicide Severity Rating Scale (C-SSRS) or as assessed by the Investigator through participant interview and review of medical history
  • A history of an adverse event (AE) to anti-TNF therapy (examples included, but were not limited, to serum sickness or anaphylaxis) for an HS or non-HS indication that would contraindicate readministration of an anti-TNF class therapy
  • Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the Investigator, participation in the study
  • Female participants who were breastfeeding or considering becoming pregnant during the study
  • History (within last 2 years prior to Baseline) of prescription drug or substance abuse, including alcohol, considered significant by the Investigator
  • Laboratory exclusion criteria applied.

The above information was not intended to contain all considerations relevant to a potential participation in a clinical trial.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
86 participants (actual)

Study arms

  • Experimental
    SAR442970

    Participants received SAR442970 once every two weeks (Q2W) in Period A (Day 1 to Week 16). Participants received SAR442970 Q2W in Period B (Up to Week 28).

    Drug: SAR442970

  • Placebo comparator
    Placebo

    Participants received placebo Q2W in Period A (Day 1 to Week 16). Participants received SAR442970 Q2W in Period B (Up to Week 28).

    Drug: Placebo

Interventions

  • 1 mL extractable volume of 150 mg/mL SAR442970 filled in 2 mL glass vial

  • DrugPlacebo

    1 mL extractable volume of placebo filled in 2 mL glass vial

06

What researchers measure

Primary outcomes

  1. Period A (DB Period): Percentage of Biologic and Small Molecule Immunosuppressive-Naïve Participants Who Achieved Hidradenitis Suppurativa Clinical Response (HiSCR50) at Week 16

    The HiSCR50 was used for assessing HS treatment effectiveness in controlling inflammatory manifestations in the population. HiSCR50 was defined as \>=50% reduction from baseline in the total abscess and inflammatory nodule (AN) count, with no increase from baseline in abscess or draining tunnel count. Baseline was defined as the last available value before the first dose of DB study drug. Percentages are rounded off to the tenth decimal place.

    Time frame: Week 16

Secondary outcomes

  1. Period A (DB Period): Time to Onset of Achieving Hidradenitis Suppurativa Clinical Response (HiSCR50)

    Time to onset of achieving HiSCR50 during the DB period was defined as the time from randomization to the first time of achieving HiSCR50 by Week 16. HiSCR50 was defined as \>=50% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count. Baseline was defined as the last available value before the first dose of DB study drug.

    Time frame: Up to Week 16

  2. Period A (DB Period): Percentage of Participants Who Achieved Hidradenitis Suppurativa Clinical Response (HiSCR75) at Week 16

    The HiSCR75 was used for assessing HS treatment effectiveness in controlling inflammatory manifestations in the population. HiSCR75 was defined as \>=75% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count. Baseline was defined as the last available value before the first dose of DB study drug.

    Time frame: Week 16

  3. Period A (DB Period): Percentage of Participants Who Achieved Hidradenitis Suppurativa Clinical Response (HiSCR90) at Week 16

    The HiSCR90 was used for assessing HS treatment effectiveness in controlling inflammatory manifestations in the population. HiSCR90 was defined as \>=90% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count. Baseline was defined as the last available value before the first dose of DB study drug.

    Time frame: Week 16

  4. Period A (DB Period): Percentage of Participants Who Experienced Improvement by at Least 1 International Hidradenitis Suppurativa Severity Score System (IHS4) Stage at Week 16

    The IHS4 was a validated tool to assess HS severity. The determination of IHS4 required counting inflammatory nodules, abscesses and draining tunnels and multiplying each by a specific coefficient. IHS4 score was calculated as: (number of inflammatory nodules multiplied by 1) + (number of abscesses multiplied by 2) + (number of draining tunnels multiplied by 4). A categorial IHS4 score was derived from this weighted score with total score range: mild: (\<=3), moderate: (4 to 10) and severe: (\>=11); higher scores indicated worse outcomes. Improvement in IHS4 by \>=1 IHS4 stage was considered clinically meaningful.

    Time frame: Week 16

  5. Period A (DB Period): Change From Baseline at Week 16 in Absolute Score in International Hidradenitis Suppurativa Severity Score System (IHS4)

    The IHS4 was a validated tool to assess HS severity. The determination of IHS4 required counting inflammatory nodules, abscesses and draining tunnels and multiplying each by a specific coefficient. IHS4 score was calculated as: (number of inflammatory nodules multiplied by 1) + (number of abscesses multiplied by 2) + (number of draining tunnels multiplied by 4). A categorial IHS4 score was derived from this weighted score with total score range: mild: (\<=3), moderate: (4 to 10) and severe: (\>=11); higher scores indicated worse outcomes. Baseline was defined as the last available value before the first dose of DB study drug.

    Time frame: Baseline (Day 1) and Week 16

  6. Period A (DB Period): Percentage of Participants Who Experienced a Flare Relative to Baseline at Week 16

    HS flare was defined as \>=25% increase in AN count with a \>=2 increase from baseline by Week 16. Baseline was defined as the last available value before the first dose of DB study drug.

    Time frame: Baseline (Day 1) and Week 16

  7. Period A (DB Period): Percentage of Participants Who Achieved International Hidradenitis Suppurativa Severity Score System (IHS4)-55 at Week 16

    The IHS4 was a validated tool to assess HS severity. The determination of IHS4 required counting inflammatory nodules, abscesses and draining tunnels and multiplying each by a specific coefficient. IHS4 score was calculated as: (number of inflammatory nodules multiplied by 1) + (number of abscesses multiplied by 2) + (number of draining tunnels multiplied by 4). A categorial IHS4 score was derived from this weighted score with total score range: mild: (\<=3), moderate: (4 to 10) and severe: (\>=11); higher scores indicated worse outcomes. IHS4-55 was defined as a 55% reduction in IHS4 score from baseline. Baseline was defined as the last available value before the first dose of DB study drug.

    Time frame: Week 16

  8. Period A (DB Period) + Period B (OLE Period): Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs) and Treatment-Emergent Adverse Events of Special Interest (TEAESIs)

    An AE as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study drug, whether or not considered related to the study drug. An SAE was defined as any untoward medical occurrence that, at any dose, resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or was an important medical event. TEAEs were AEs that developed, worsened or became serious during the TE period. An AESI was an AE (serious or non-serious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor was required.

    Time frame: Period A was assessed from first dose of study drug (Day 1 in Period A) up to last dose of study drug + 75 days, up to 192 days; Period B was assessed from first dose in Period B to last dose of study drug + 75 days, up to 168 days

  9. Period A (DB Period): Percentage of Participants Who Achieved at Least 30% Reduction and at Least 1 Unit Reduction From Baseline in Weekly Average of Daily Hidradenitis Suppurativa Skin Pain Numeric Rating Scale (HS-Skin Pain NRS) at Week 16

    The HS-Skin Pain NRS was a unidimensional numeric rating scale (NRS) that allowed for rapid measure of skin pain that was administered multiple times with minimal administrative burden. The HS-Skin Pain NRS had a 24-hour recall period and was completed as a daily diary, ideally at the same time each day (evening) throughout the treatment period. Participants were asked to complete the HS-Skin Pain NRS for 7 consecutive days leading up to the baseline visit with a minimum of 4 completions in their daily diary. The HS-Skin Pain NRS was scored on a 0 to 10 scale; 0: no skin pain and 10: worst skin pain possible. Higher scores indicated worse outcomes. Baseline was defined as the last available value before the first dose of DB study drug.

    Time frame: Baseline (Day 1) and Week 16

  10. Period A (DB Period) + Period B (OLE Period): Serum SAR442970 Concentrations

    Blood samples were collected at specified timepoints for assessment of serum SAR442970 concentrations.

    Time frame: Baseline (Day 1), Weeks 4, 8, 10, 12 and 16 (Period A); Weeks 18, 20 and 28 (Period B)

  11. Period B (OLE Period) + Period A+B (DB+OLE Period): Number of Participants With Anti-SAR442970 Antibody Response

    Serum samples were collected at specified timepoints for assessment of anti-SAR442970 antibody response. Treatment-emergent anti-drug antibody (ADA) were defined as participants with at least 1 treatment-induced/boosted ADA at any time after first study drug administration up to the last available ADA sample collection. Number of participants with treatment-emergent ADA response are presented.

    Time frame: Period B: Placebo-SAR442970 arm were assessed from first dose of study drug in Period B up to approximately 20 weeks. Period A+B: SAR442970-SAR442970 arm were assessed from first dose of study drug in Period A up to 36 weeks

07

Results

Posted Jan 29, 2026

Participant flow

The study started to screen participants in June 2023 and concluded enrollment in April 2024.

Period A (DB): Up to Week 16
Participant flow — Period A (DB): Up to Week 16
MilestonePeriod A: PlaceboPeriod A: SAR442970Period B: Placebo-SAR442970Period B: SAR442970-SAR442970
Started285800
Completed265200
Not completed2600
Withdrew: Withdrawal by subject1100
Withdrew: Other1300
Withdrew: Adverse event0200
Period B (OLE): From Week 16 to Week 28
Participant flow — Period B (OLE): From Week 16 to Week 28
MilestonePeriod A: PlaceboPeriod A: SAR442970Period B: Placebo-SAR442970Period B: SAR442970-SAR442970
Started002651
Completed002445
Not completed0026
Withdrew: Adverse event0001
Withdrew: Non-compliance with study schedule0001
Withdrew: Withdrawal by subject0021
Withdrew: Other0002
Withdrew: Non-compliance with study drug0001

Outcome measures

PrimaryPeriod A (DB Period): Percentage of Biologic and Small Molecule Immunosuppressive-Naïve Participants Who Achieved Hidradenitis Suppurativa Clinical Response (HiSCR50) at Week 16

The HiSCR50 was used for assessing HS treatment effectiveness in controlling inflammatory manifestations in the population. HiSCR50 was defined as \>=50% reduction from baseline in the total abscess and inflammatory nodule (AN) count, with no increase from baseline in abscess or draining tunnel count. Baseline was defined as the last available value before the first dose of DB study drug. Percentages are rounded off to the tenth decimal place.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Period A (DB Period): Percentage of Biologic and Small Molecule Immunosuppressive-Naïve Participants Who Achieved Hidradenitis Suppurativa Clinical Response (HiSCR50) at Week 16
percentage of participantsPeriod A: PlaceboPeriod A: SAR442970
Period A (DB Period): Percentage of Biologic and Small Molecule Immunosuppressive-Naïve Participants Who Achieved Hidradenitis Suppurativa Clinical Response (HiSCR50) at Week 1639.166.7
Statistical analysis
  • Period A: Placebo vs Period A: SAR442970 · Median posterior rr difference: 29 · 90% CI 10 to 47
  • Period A: Placebo vs Period A: SAR442970 · Pr[diff > 0%](%): 99.3
SecondaryPeriod A (DB Period): Time to Onset of Achieving Hidradenitis Suppurativa Clinical Response (HiSCR50)

Time to onset of achieving HiSCR50 during the DB period was defined as the time from randomization to the first time of achieving HiSCR50 by Week 16. HiSCR50 was defined as \>=50% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count. Baseline was defined as the last available value before the first dose of DB study drug.

Time frame:
Up to Week 16
Reported as:
Median · days
Period A (DB Period): Time to Onset of Achieving Hidradenitis Suppurativa Clinical Response (HiSCR50)
daysPeriod A: PlaceboPeriod A: SAR442970
Period A (DB Period): Time to Onset of Achieving Hidradenitis Suppurativa Clinical Response (HiSCR50)113.00 (29.000 to NA)29.00 (17.000 to 29.000)
SecondaryPeriod A (DB Period): Percentage of Participants Who Achieved Hidradenitis Suppurativa Clinical Response (HiSCR75) at Week 16

The HiSCR75 was used for assessing HS treatment effectiveness in controlling inflammatory manifestations in the population. HiSCR75 was defined as \>=75% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count. Baseline was defined as the last available value before the first dose of DB study drug.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Period A (DB Period): Percentage of Participants Who Achieved Hidradenitis Suppurativa Clinical Response (HiSCR75) at Week 16
percentage of participantsPeriod A: PlaceboPeriod A: SAR442970
Period A (DB Period): Percentage of Participants Who Achieved Hidradenitis Suppurativa Clinical Response (HiSCR75) at Week 1621.754.2
SecondaryPeriod A (DB Period): Percentage of Participants Who Achieved Hidradenitis Suppurativa Clinical Response (HiSCR90) at Week 16

The HiSCR90 was used for assessing HS treatment effectiveness in controlling inflammatory manifestations in the population. HiSCR90 was defined as \>=90% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count. Baseline was defined as the last available value before the first dose of DB study drug.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Period A (DB Period): Percentage of Participants Who Achieved Hidradenitis Suppurativa Clinical Response (HiSCR90) at Week 16
percentage of participantsPeriod A: PlaceboPeriod A: SAR442970
Period A (DB Period): Percentage of Participants Who Achieved Hidradenitis Suppurativa Clinical Response (HiSCR90) at Week 168.731.3
SecondaryPeriod A (DB Period): Percentage of Participants Who Experienced Improvement by at Least 1 International Hidradenitis Suppurativa Severity Score System (IHS4) Stage at Week 16

The IHS4 was a validated tool to assess HS severity. The determination of IHS4 required counting inflammatory nodules, abscesses and draining tunnels and multiplying each by a specific coefficient. IHS4 score was calculated as: (number of inflammatory nodules multiplied by 1) + (number of abscesses multiplied by 2) + (number of draining tunnels multiplied by 4). A categorial IHS4 score was derived from this weighted score with total score range: mild: (\<=3), moderate: (4 to 10) and severe: (\>=11); higher scores indicated worse outcomes. Improvement in IHS4 by \>=1 IHS4 stage was considered clinically meaningful.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Period A (DB Period): Percentage of Participants Who Experienced Improvement by at Least 1 International Hidradenitis Suppurativa Severity Score System (IHS4) Stage at Week 16
percentage of participantsPeriod A: PlaceboPeriod A: SAR442970
Period A (DB Period): Percentage of Participants Who Experienced Improvement by at Least 1 International Hidradenitis Suppurativa Severity Score System (IHS4) Stage at Week 1656.583.3
SecondaryPeriod A (DB Period): Change From Baseline at Week 16 in Absolute Score in International Hidradenitis Suppurativa Severity Score System (IHS4)

The IHS4 was a validated tool to assess HS severity. The determination of IHS4 required counting inflammatory nodules, abscesses and draining tunnels and multiplying each by a specific coefficient. IHS4 score was calculated as: (number of inflammatory nodules multiplied by 1) + (number of abscesses multiplied by 2) + (number of draining tunnels multiplied by 4). A categorial IHS4 score was derived from this weighted score with total score range: mild: (\<=3), moderate: (4 to 10) and severe: (\>=11); higher scores indicated worse outcomes. Baseline was defined as the last available value before the first dose of DB study drug.

Time frame:
Baseline (Day 1) and Week 16
Reported as:
Mean · score on a scale
Period A (DB Period): Change From Baseline at Week 16 in Absolute Score in International Hidradenitis Suppurativa Severity Score System (IHS4)
score on a scalePeriod A: PlaceboPeriod A: SAR442970
Period A (DB Period): Change From Baseline at Week 16 in Absolute Score in International Hidradenitis Suppurativa Severity Score System (IHS4)-7.3 ± 19.5-18.1 ± 18.6
SecondaryPeriod A (DB Period): Percentage of Participants Who Experienced a Flare Relative to Baseline at Week 16

HS flare was defined as \>=25% increase in AN count with a \>=2 increase from baseline by Week 16. Baseline was defined as the last available value before the first dose of DB study drug.

Time frame:
Baseline (Day 1) and Week 16
Reported as:
Number · percentage of participants
Period A (DB Period): Percentage of Participants Who Experienced a Flare Relative to Baseline at Week 16
percentage of participantsPeriod A: PlaceboPeriod A: SAR442970
Period A (DB Period): Percentage of Participants Who Experienced a Flare Relative to Baseline at Week 1630.416.7
SecondaryPeriod A (DB Period): Percentage of Participants Who Achieved International Hidradenitis Suppurativa Severity Score System (IHS4)-55 at Week 16

The IHS4 was a validated tool to assess HS severity. The determination of IHS4 required counting inflammatory nodules, abscesses and draining tunnels and multiplying each by a specific coefficient. IHS4 score was calculated as: (number of inflammatory nodules multiplied by 1) + (number of abscesses multiplied by 2) + (number of draining tunnels multiplied by 4). A categorial IHS4 score was derived from this weighted score with total score range: mild: (\<=3), moderate: (4 to 10) and severe: (\>=11); higher scores indicated worse outcomes. IHS4-55 was defined as a 55% reduction in IHS4 score from baseline. Baseline was defined as the last available value before the first dose of DB study drug.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Period A (DB Period): Percentage of Participants Who Achieved International Hidradenitis Suppurativa Severity Score System (IHS4)-55 at Week 16
percentage of participantsPeriod A: PlaceboPeriod A: SAR442970
Period A (DB Period): Percentage of Participants Who Achieved International Hidradenitis Suppurativa Severity Score System (IHS4)-55 at Week 1634.864.6
SecondaryPeriod A (DB Period) + Period B (OLE Period): Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs) and Treatment-Emergent Adverse Events of Special Interest (TEAESIs)

An AE as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study drug, whether or not considered related to the study drug. An SAE was defined as any untoward medical occurrence that, at any dose, resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or was an important medical event. TEAEs were AEs that developed, worsened or became serious during the TE period. An AESI was an AE (serious or non-serious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor was required.

Time frame:
Period A was assessed from first dose of study drug (Day 1 in Period A) up to last dose of study drug + 75 days, up to 192 days; Period B was assessed from first dose in Period B to last dose of study drug + 75 days, up to 168 days
Reported as:
Count of participants · Participants
Period A (DB Period) + Period B (OLE Period): Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs) and Treatment-Emergent Adverse Events of Special Interest (TEAESIs)
ParticipantsPeriod A: PlaceboPeriod A: SAR442970Period B: Placebo-SAR442970Period B: SAR442970-SAR442970
Any TEAEs15451430
Any TESAEs0000
Any TEAESIs0302
SecondaryPeriod A (DB Period): Percentage of Participants Who Achieved at Least 30% Reduction and at Least 1 Unit Reduction From Baseline in Weekly Average of Daily Hidradenitis Suppurativa Skin Pain Numeric Rating Scale (HS-Skin Pain NRS) at Week 16

The HS-Skin Pain NRS was a unidimensional numeric rating scale (NRS) that allowed for rapid measure of skin pain that was administered multiple times with minimal administrative burden. The HS-Skin Pain NRS had a 24-hour recall period and was completed as a daily diary, ideally at the same time each day (evening) throughout the treatment period. Participants were asked to complete the HS-Skin Pain NRS for 7 consecutive days leading up to the baseline visit with a minimum of 4 completions in their daily diary. The HS-Skin Pain NRS was scored on a 0 to 10 scale; 0: no skin pain and 10: worst skin pain possible. Higher scores indicated worse outcomes. Baseline was defined as the last available value before the first dose of DB study drug.

Time frame:
Baseline (Day 1) and Week 16
Reported as:
Number · percentage of participants
Period A (DB Period): Percentage of Participants Who Achieved at Least 30% Reduction and at Least 1 Unit Reduction From Baseline in Weekly Average of Daily Hidradenitis Suppurativa Skin Pain Numeric Rating Scale (HS-Skin Pain NRS) at Week 16
percentage of participantsPeriod A: PlaceboPeriod A: SAR442970
Period A (DB Period): Percentage of Participants Who Achieved at Least 30% Reduction and at Least 1 Unit Reduction From Baseline in Weekly Average of Daily Hidradenitis Suppurativa Skin Pain Numeric Rating Scale (HS-Skin Pain NRS) at Week 1640.040.6
SecondaryPeriod A (DB Period) + Period B (OLE Period): Serum SAR442970 Concentrations

Blood samples were collected at specified timepoints for assessment of serum SAR442970 concentrations.

Time frame:
Baseline (Day 1), Weeks 4, 8, 10, 12 and 16 (Period A); Weeks 18, 20 and 28 (Period B)
Reported as:
Mean · nanogram per milliliter
Period A (DB Period) + Period B (OLE Period): Serum SAR442970 Concentrations
nanogram per milliliterPeriod A: SAR442970Period B: Placebo-SAR442970Period B: SAR442970-SAR442970
Baseline (Day 1)0.00 ± 0.00——
Week 46451.21 ± 2252.03——
Week 87729.59 ± 2957.15——
Week 108091.69 ± 5141.56——
Week 129486.51 ± 8715.72——
Week 168844.81 ± 5908.33——
Week 18—4696.96 ± 1941.047996.88 ± 3716.46
Week 20—5693.20 ± 2223.458339.58 ± 4192.17
Week 28—7291.30 ± 3197.028513.07 ± 6868.14
SecondaryPeriod B (OLE Period) + Period A+B (DB+OLE Period): Number of Participants With Anti-SAR442970 Antibody Response

Serum samples were collected at specified timepoints for assessment of anti-SAR442970 antibody response. Treatment-emergent anti-drug antibody (ADA) were defined as participants with at least 1 treatment-induced/boosted ADA at any time after first study drug administration up to the last available ADA sample collection. Number of participants with treatment-emergent ADA response are presented.

Time frame:
Period B: Placebo-SAR442970 arm were assessed from first dose of study drug in Period B up to approximately 20 weeks. Period A+B: SAR442970-SAR442970 arm were assessed from first dose of study drug in Period A up to 36 weeks
Reported as:
Count of participants · Participants
Period B (OLE Period) + Period A+B (DB+OLE Period): Number of Participants With Anti-SAR442970 Antibody Response
ParticipantsPeriod B: Placebo-SAR442970Period A+B: SAR442970-SAR442970
Period B (OLE Period) + Period A+B (DB+OLE Period): Number of Participants With Anti-SAR442970 Antibody Response1845

Adverse events

Collected over AEs and SAEs: Period A was assessed from first dose of study drug (Day 1 in Period A) up to last dose of study drug + 75 days, up to 192 days; Period B was assessed from first dose in Period B to last dose of study drug + 75 days, up to 168 days. All-cause mortality (deaths) were collected from the first dose of study drug to the end of follow-up for death for each participant, up to approximately 583 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Period A: Placebo0/28 (0%)0/28 (0%)11/28 (39.3%)
Period A: SAR4429700/58 (0%)0/58 (0%)32/58 (55.2%)
Period B: Placebo-SAR4429700/26 (0%)0/26 (0%)6/26 (23.1%)
Period B: SAR442970-SAR4429700/51 (0%)0/51 (0%)16/51 (31.4%)
Most frequent other events
Most frequent other events
EventPeriod A: PlaceboPeriod A: SAR442970Period B: Placebo-SAR442970Period B: SAR442970-SAR442970
NasopharyngitisInfections and infestations3/2811/580/261/51
Accidental OverdoseInjury, poisoning and procedural complications4/287/581/263/51
HeadacheNervous system disorders3/288/582/264/51
Upper Respiratory Tract InfectionInfections and infestations1/284/582/264/51
HidradenitisSkin and subcutaneous tissue disorders1/283/582/262/51
HypertriglyceridaemiaMetabolism and nutrition disorders2/282/580/260/51
Pain Of SkinSkin and subcutaneous tissue disorders0/281/580/263/51
PsoriasisSkin and subcutaneous tissue disorders0/283/580/261/51
Injection Site ReactionGeneral disorders0/283/580/260/51

Baseline characteristics

The randomized population included all participants from screened population who were allocated to a randomized study drug by interactive response technology regardless of whether the study drug was received or not.

Age, Continuous
Age, Continuous(years)Period A: PlaceboPeriod A: SAR442970Total
Mean37.0 ± 13.236.3 ± 12.236.5 ± 12.5
Sex: Female, Male
Sex: Female, Male(Participants)Period A: PlaceboPeriod A: SAR442970Total
Female153853
Male132033
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Period A: PlaceboPeriod A: SAR442970Total
American Indian or Alaska Native011
Asian303
Native Hawaiian or Other Pacific Islander000
Black or African American235
White165066
More than one race000
Unknown or Not Reported7411
08

Study locations

45 sites
  • Medical Dermatology Specialists Site Number : 8400007
    Phoenix, Arizona 85006, United States
  • Renstar Medical Research Site Number : 8400011
    Ocala, Florida 34470, United States
  • ForCare Clinical Research Site Number : 8400006
    Tampa, Florida 33613, United States
  • Advanced Medical Research PC Site Number : 8400002
    Sandy Springs, Georgia 30328, United States
  • Clinical Partners, LLC Site Number : 8400010
    Johnston, Rhode Island 02919, United States
  • Center for Clinical Studies, LTD. LLP Site Number : 8400003
    Houston, Texas 77004, United States
  • Investigational Site Number : 0360002
    Liverpool, New South Wales 2170, Australia
  • Investigational Site Number : 0360003
    Woolloongabba, Queensland 4102, Australia
  • Investigational Site Number : 0560001
    Leuven, 3000, Belgium
  • Investigational Site Number : 1240001
    Barrie, Ontario L4M 7G1, Canada
  • Investigational Site Number : 1240002
    London, Ontario N6H 5L5, Canada
  • Investigational Site Number : 1240004
    Newmarket, Ontario L3Y 5G8, Canada
  • Investigational Site Number : 1240007
    Québec, G1V 4T3, Canada
  • Investigational Site Number : 1520003
    Santiago, Reg Metropolitana de Santiago 7580206, Chile
  • Investigational Site Number : 1520001
    Santiago, Reg Metropolitana de Santiago 7640881, Chile
  • Investigational Site Number : 1520002
    Santiago, Reg Metropolitana de Santiago 8420383, Chile
  • Investigational Site Number : 2030003
    Ostrava - Poruba, 70852, Czechia
  • Investigational Site Number : 2030001
    Prague, 10034, Czechia
  • Investigational Site Number : 2030002
    Praha 5 - Motol, 15006, Czechia
  • Investigational Site Number : 2080001
    Roskilde, 4000, Denmark
  • Investigational Site Number : 2500001
    Lyon, 69003, France
  • Investigational Site Number : 2500002
    Nice, 06200, France
  • Investigational Site Number : 2500003
    Reims, 51100, France
  • Investigational Site Number : 2760005
    Berlin, 10117, Germany
  • Investigational Site Number : 2760008
    Bochum, 44791, Germany
  • Investigational Site Number : 2760002
    Frankfurt am Main, 60590, Germany
  • Investigational Site Number : 2760004
    Mainz, 55131, Germany
  • Investigational Site Number : 2760001
    Münster, 48149, Germany
  • Investigational Site Number : 3000003
    Athens, 12462, Greece
  • Investigational Site Number : 3000001
    Athens, 16121, Greece
  • Investigational Site Number : 3800001
    Milan, Lombardy 20122, Italy
  • Investigational Site Number : 3800002
    Rozzano, Lombardy 20089, Italy
  • Investigational Site Number : 3800003
    Catania, 95123, Italy
  • Investigational Site Number : 5280001
    Groningen, 9713 GZ, Netherlands
  • Investigational Site Number : 5280003
    Rotterdam, 3015 GD, Netherlands
  • Investigational Site Number : 6160001
    Warsaw, Masovian Voivodeship 02-507, Poland
  • Investigational Site Number : 6160004
    Lodz, 90265, Poland
  • Investigational Site Number : 6160003
    Wroclaw, 50-566, Poland
  • Investigational Site Number : 6160002
    Wroclaw, 51-685, Poland
  • Investigational Site Number : 7240003
    Barcelona, Barcelona [Barcelona] 08041, Spain
  • Investigational Site Number : 7240006
    Madrid, Madrid, Comunidad de 28046, Spain
  • Investigational Site Number : 7240001
    Madrid / Madrid, Madrid, Comunidad de 28007, Spain
  • Investigational Site Number : 7240004
    Manises, Valencia 46940, Spain
  • Investigational Site Number : 7240005
    Córdoba, 14004, Spain
  • Investigational Site Number : 7520001
    Älvsjö, 125 44, Sweden
09

References and documents

Publications

  • Lin J, Radhakrishnan J. What Are Baskets, Umbrellas, and Platforms Doing in Nephrology Clinical Trials? J Am Soc Nephrol. 2025 Feb 3;36(8):1652-1654. doi: 10.1681/ASN.0000000648. No abstract available. PubMed 39899371 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized, and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2023 to primary completion in Aug 2024, 14 months.

Results were first posted in Jan 2026, 1 year 5 months after primary completion. A results delay was requested in Aug 2025.

Of 44 industry-sponsored phase 2 interventional studies under Hidradenitis Suppurativa, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 14 months is close to that.

Counting every sponsor, half of 54 studies reached it within 15 months; a quarter within 11 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2023
First posted
May 9, 2023
StartActual
Jun 6, 2023
Primary completionActual
Aug 22, 2024
CompletionActual
Jan 9, 2025
Results delay requested
Aug 7, 2025
Results first posted
Jan 29, 2026
Last update
Jan 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05849922
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
May 9, 2023
Start date
Jun 6, 2023
Primary completion
Aug 22, 2024
Completion
Jan 9, 2025
Results posted
Jan 29, 2026
Last update
Jan 29, 2026

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brivekimig

Start the discussion